ONCOLYTICS BIOTECH INC 8-K

What Happened On February 24, 2026, Oncolytics Biotech, Inc. (ONCY) filed an Form 8‑K and issued a press release stating the company will prioritize registrational or registration‑enabling clinical studies in colorectal and anal cancer. The company also announced it has concluded enrollment in its GOBLET gastrointestinal cancer study. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: February 24, 2026 (Form 8‑K; press release attached as Exhibit 99.1).
• Strategic focus: prioritize registrational or registration‑enabling studies in colorectal and anal cancer.
• Clinical update: enrollment in the GOBLET gastrointestinal cancer study has been concluded.
• Form signed on behalf of the company by CFO Kirk Look.

Why It Matters This 8‑K signals a strategic shift toward late‑stage, registration‑focused development in specific tumor types (colorectal and anal), which could accelerate pathways to regulatory submissions if clinical data are positive. Concluding enrollment in the GOBLET study is a tangible operational milestone that may enable upcoming data readouts or analyses. Retail investors should watch for follow‑up announcements on study timelines, data releases, and any planned registrational study designs or regulatory interactions.